603231 索宝蛋白
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)3.3989.7766.36510.67122.544
总资产报酬率 ROA (%)2.9708.7155.6758.76615.854
投入资产回报率 ROIC (%)3.2759.5826.1459.92719.653

边际利润分析
销售毛利率 (%)12.94916.68312.00713.57613.266
营业利润率 (%)8.30512.9889.53410.27210.250
息税前利润/营业总收入 (%)9.13312.6118.4479.8629.835
净利润/营业总收入 (%)6.94310.8537.7918.3509.099

收益指标分析
经营活动净收益/利润总额(%)91.91393.41683.22395.26998.452
价值变动净收益/利润总额(%)4.7873.6298.0110.013-0.241
营业外收支净额/利润总额(%)-0.236-1.541-2.925-4.257-0.249

偿债能力分析
流动比率 (X)5.4225.6326.7966.3251.590
速动比率 (X)4.1594.6315.3325.4110.838
资产负债率 (%)13.55211.56810.08511.53929.897
带息债务/全部投入资本 (%)2.5401.0240.9124.0399.644
股东权益/带息债务 (%)3,736.4589,564.68410,752.3362,355.095915.871
股东权益/负债合计 (%)637.574764.442891.596766.645234.485
利息保障倍数 (X)10.779-70.161-10.348951.088-25.258

营运能力分析
应收账款周转天数 (天)28.31330.09937.41533.48826.490
存货周转天数 (天)61.00164.40365.04154.65648.619